Cullinan Therapeutics CLN-978 & Velinotamig Show Positive Autoimmune Data
Cullinan Therapeutics reported positive clinical data for its T cell engagers, CLN-978 (CD19 TCE) and velinotamig (BCMA TCE), in autoimmune diseases. CLN-978 demonstrated potential for immune reset and remissions in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), showing robust efficacy and a favorable safety profile in multi-dose regimens. Initial velinotamig data also showed promising clinical activity, including complete renal responses in lupus nephritis, supporting its potential in plasma cell-driven autoimmune diseases. The company plans further development, including Phase 2a expansion for CLN-978 in early 2027 and a Phase 1/2a trial for velinotamig in autoimmune cytopenias in Q1 2027, with additional data expected in Q3 and Q4 2026.
Key Highlights
- CLN-978 EULAR data showed potential for immune reset and remissions in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
- CLN-978 multi-dose regimen in RA demonstrated robust efficacy, including clinical remission in a poly-refractory patient.
- CLN-978 safety profile in SLE multi-dose regimen was consistent with the favorable profile in the initial RA cohort.
- Initial velinotamig data showed promising clinical activity, including complete renal responses in lupus nephritis.
- Velinotamig demonstrated a favorable safety profile with no cytokine release syndrome (CRS) or ICANS observed in two SLE patients.
- Cullinan plans to report additional multi-dose data for CLN-978 in RA in Q3 2026 and in SLE in Q4 2026.
- Cullinan plans to initiate CLN-978 Phase 2a expansion in lupus nephritis in early 2027.
- Cullinan plans to initiate a velinotamig Phase 1/2a clinical trial in autoimmune cytopenias in Q1 2027.
Price Impact
More from CGEM